Earli

Earli is a private, pre-clinical stage biotech founded in 2018, pioneering a novel approach to cancer treatment and detection. Its core technology uses AI to design genetic switches delivered via proprietary lipid nanoparticles (cancerLNPs) that activate only in cancer cells, programming them to produce immune-stimulating therapies locally within the tumor. This 'Cancer Against Itself' strategy aims to enhance the efficacy and safety of immuno-oncology by avoiding systemic toxicity. The company has garnered significant attention, substantial venture funding, and recognition from initiatives like the White House Cancer Moonshot.

AI-designed genetic switches delivered via proprietary lipid nanoparticles (cancerLNPs) that activate exclusively in cancer cells, programming them to produce immune therapies in vivo.

Earli competes in the targeted cancer therapy space with companies developing tumor-localized therapies, oncolytic viruses, and other gene circuit approaches. Its direct competition includes other biotechs using synthetic biology for conditional expression. Its broader competition includes all immuno-oncology companies seeking to improve checkpoint inhibitor efficacy and safety profiles.